Mounjaro (tirzepatide) : Lilly's dual GIP/GLP-1 agonist has delivered best-in-class weight loss and glycemic control in T2D and, under its obesity brand Zepbound , has outperformed semaglutide in head ...

Many Mounjaro users have considered making the swap after Eli Lilly announced prices would be increasing in the UK by 170 percent ...

Twice as many employers as last year say they are planning to pull back on filling jobs, according to a new Conference Board survey.